A Neurological Frontier With Global Commercial Stakes
From Tokyo to London, pharmaceutical researchers have spent two decades mapping the orexin system — a network of brain signalling molecules that regulates sleep, wakefulness, appetite, and arousal. That work has already produced approved sleep medications sold across North America, Europe, and Asia. Now, UK-based clinical-stage developer Centessa Pharmaceuticals, operating in partnership with Japan's Nxera Pharma, is pushing into riskier and potentially more lucrative territory: drugs that activate orexin receptors rather than suppress them.
The two lead candidates — ORX750 and ORX142 — are designed to treat conditions like narcolepsy type 1 and idiopathic hypersomnia, disorders that collectively affect millions of people worldwide yet remain chronically undertreated. The World Health Organisation estimates that sleep disorders cost global economies hundreds of billions of dollars annually in lost productivity, yet first-line pharmacological options remain limited and often poorly tolerated.
Antagonists vs. Agonists: The Mechanistic Fork in the Road
The orexin pathway has already yielded two approved drug classes. Suvorexant — marketed as Belsomra by US giant Merck — and lemborexant, sold as Dayvigo by Japan's Eisai, are orexin antagonists: they block orexin receptors to promote sleep and are approved across the United States, Japan, and multiple European markets. Their regulatory track record provides a safety benchmark, however limited, for the antagonist mechanism.
Orexin agonists are the pharmacological mirror image. Rather than suppressing the system, they stimulate it — a mechanism that has never been validated in an approved human medicine. That gap in the evidence base is where the risk concentrates. No regulatory authority, whether the US FDA, the European Medicines Agency, Japan's PMDA, or the UK's MHRA, has yet assessed the long-term safety profile of chronic orexin receptor stimulation at therapeutic doses in humans.
On-Target Risks That Cannot Be Engineered Away
Unlike off-target side effects, which can sometimes be resolved through chemical modifications, the risks flagged in Centessa's orexin agonist programme arise directly from the drug working as intended. Researchers across the field have identified several plausible adverse outcomes:
- Paradoxical narcolepsy-like episodes caused by receptor desensitisation — a phenomenon observed in other agonist drug classes globally, from opioids to dopamine agonists used in Parkinson's disease
- Cardiovascular consequences, since orexin receptors play a documented role in autonomic regulation of blood pressure and heart rate — a concern with particular relevance in ageing populations across Europe, North America, and East Asia
- Psychiatric effects including anxiety, agitation, or dysphoria, consistent with hyperactivation of arousal pathways — adverse outcomes that global regulators have grown increasingly attentive to following high-profile withdrawals in the CNS drug space
These risks cannot be neutralised through reformulation or dosing adjustments alone, because they reflect the drug's core pharmacology.
The Investment Calculus in a Global Drug Development Market
For investors — whether institutional funds in New York, sovereign wealth vehicles in the Gulf, or biotech-focused portfolios in Europe — modelling Centessa's pipeline value requires confronting an uncomfortable asymmetry. The orexin agonist market opportunity is substantial: narcolepsy affects an estimated 3 million people in the United States and European Union alone, with significant underdiagnosis in developing markets across South Asia, Latin America, and Sub-Saharan Africa. Commercial success could be worth billions in peak annual revenues.
But the risk-adjusted net present value (rNPV) of the programme must account for a failure scenario classified by analysts as catastrophic in severity. A clinical hold, a serious adverse event signal, or a regulatory rejection would not merely delay the programme — it could permanently impair the asset and raise systemic questions about the entire orexin agonist class globally, affecting competitor pipelines at firms including Jazz Pharmaceuticals, Takeda, and a range of emerging biotech players in the United States, China, and Europe.
A Cross-Border Partnership Under Pressure
The Centessa–Nxera collaboration itself reflects the increasingly internationalised nature of neurological drug development. The partnership combines Centessa's clinical infrastructure with Nxera's research heritage — a model that has become standard in a sector where no single country dominates the science, the capital, or the regulatory pathways. Japan has been a pioneer in sleep disorder pharmacology; the United States remains the dominant commercial market; and European regulators have set increasingly stringent standards for CNS drug approvals following a series of high-profile post-market withdrawals.
That globalised development environment means that a safety failure in this programme would reverberate across multiple jurisdictions simultaneously, compounding financial exposure for investors with cross-border portfolios.
What the Global Medical Community Is Watching
Beyond the investment implications, the clinical outcome of Centessa's agonist programme carries broader scientific significance. If ORX750 or ORX142 can demonstrate a clean safety profile through Phase II and Phase III trials, they would represent the first validated proof of concept for chronic orexin agonism in humans — a finding that would reshape understanding of the orexin system and potentially open treatment pathways for conditions ranging from narcolepsy to depression and cognitive decline, areas of acute unmet need across both high-income and lower-income countries.
The orexin system does not respect national borders. Neither will the consequences — positive or negative — of what Centessa learns in its clinic.
Sources:
1 Yahoo Finance, "3 weeks of war, possible rate hikes, and AI's 'show me' phase: What to watch this week" (March 22, 2026)
2 Globe Newswire, "Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1" (March 12, 2026)
3 Globe Newswire, "Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals" (March 05, 2026)
4 Yahoo Finance, "Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%" (February 23, 2026)